| Name | Title | Contact Details |
|---|---|---|
Edward Ryan |
Sr. Dir, IT, Office of CIO | Profile |
Annlea Rumfola |
EVP, Chief Information Officer | Profile |
Heather Knight |
Chief Operating Officer | Profile |
Chris Toth |
Chief Executive Officer | Profile |
Carl Jenkins |
Associate General Counsel, Legal-Regulatory | Profile |
Chindex International, Inc. (Chindex) is engaged in the provision of healthcare services and the sale of medical equipment, instrumentation, and products in several healthcare markets in China, including Hong Kong. The Company operates in two business
Spero Health, Inc., is an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorders with a mission to “Save Lives, Instill Hope, and Restore Relationships.” Spero Health utilizes an innovative evidenced-based integrated care model that combines both physical and behavioral healthcare services under one roof to treat the whole patient. This integrated care model combines physician services (including medication-assisted treatment), behavioral health counseling, recovery support services, medication management and patient and family education. Its community-based approach to treatment allows patients to continue working and caring for their families as they overcome addiction. Based in Nashville, Tenn. and privately held by Heritage Group, Health Velocity Capital, South Central, Inc. and Frist Cressey Ventures, Spero Health operates 23 freestanding outpatient clinics located throughout Kentucky, Ohio and Indiana. Providing care for more than 5,300 patients each month, Spero is one of the largest office-based opioid treatment providers in the country and is in network with Medicaid and most commercial insurance plans.
B Braun McGaw is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Procyrion is developing the first catheter-deployed circulatory assist device intended for long-term use. The Procyrion device will be the first minimally invasive tool for cardiologists to treat over 1M NYHA Class III and early class IV heart failure (HF) patients in the US who have few therapeutic options. In partnership with Texas Heart Institute, Procyrion is currently conducting preclinical testing of the Procyrion device.
DGH Technology is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.